Aurobindo Pharma profit after tax up 355 per cent in Dec qtr

Aurobindo Pharma today said its Profit After Tax for the quarter ended December 31 is up by nearly 355 per cent to Rs 417.5 crore, backed primarily by robust sales from the US.
The PAT for the same quarter in the FY 13 was at Rs 91.8 crore, Aurobindo said in a statement.
The total operating income was up by over 36 per cent at Rs 2,140.6 crore during the quarter under discussion against Rs 1,570.1 crore in the October-December quarter last year.
N Govindarajan, Managing Director of the company, said "We have had a robust quarter driven by our sustaining base business along with successful launches in US, translating into better top and bottom line.

"We are confident to sustain the momentum as we foray into strengthening our access into markets, products and technology platforms where we are not dominantly present as we consolidate on our existing businesses."
Revenues from the US stood at 931.2 crore up 81.4 per cent against Rs 513.4 crore during the same quarter in FY 13.
The company has received approvals for six new drugs each from US FDA and health Canada, two from South Africa and one from Australia during the quarter, Aurobindo said.
The company said it has 188 cumulative approvals including 25 tentative by USFDA, 66 cumulative approvals by MCC of South Africa, 47 cumulative approvals by TGA of Australia and 45 cumulative approvals by Health Canada.